DA-001

Small molecule

AApplied Biology, Inc.

DA-001 is one of 35 small molecule programs targeting Growth. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

GrowthPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Lovenox

Sanofi

Preclinical

2 3

Aricept

Eisai

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Herceptin

OOrganon and Co

Preclinical

4 7

Somavaratan

Glucophage

2 9

EGRIFTA WR

TTheratechnologies

Preclinical

2 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Not yet recruiting

Growth

NCT06648850

Clinical

Trials by Indication[1]

Growth1 trial

Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth

Not yet recruiting·AApplied Biology, Inc.·Phase 2/3·NCT06648850·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DA-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Applied Biology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: AApplied Biology, Inc.

DA-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Growth1 trial

References

Drug Info

Quick Facts

Related News